Vildagliptin in diabetic type 2 patients with cardiovascular risk or renal impairment. Review of the literatura.
Journal Title: Revista Cuarzo - Year 2018, Vol 24, Issue 1
Abstract
Introduction: Commonly prescribed agents for the treatment of type 2 diabetes (T2DM) have restrictions on use in patients with car-diovascular or renal function impairment. Published studies on dipeptidyl peptidase-4 inhibitors (DPP-4I) indicate that these agents are suitable for use in this patient population. However, in everyday clinical practice, uncertainties prevail regarding the effectiveness and safety of appropriately prescribing the DPP-4I, specifically in patients in whom the risk or presence of cardiovascular or renal disease is present. This literature review integrates studies published between 2015 -2018 on safety, efficacy and use of vildagliptin in patients with DM2 at risk of events or cardiovascular disease, impaired renal function, or both. Method: literature review that extends from 01-01- 2015 to 31-05- 2018, focuses on the safety, efficacy and clinical use of vildagliptin in adult patients with DM2 at risk of event, or cardiovascular disease, or impaired renal function, or both. Results: three real world data studies, six ECCA, two network meta-analyses, nine systematic reviews, and three observational stu-dies integrate the unit of analysis that presents in narrative synthesis on the effectiveness and safety of the DPP-4I vildagliptin in the context of diabetic patients with cardiovascular risk and impaired renal function. Conclusion: this review reiterates the transcendence of comprehensive, effective and safe interventions for metabolic control in peo-ple with DBT, specifically for patients in whom cardiovascular disease, deterioration of renal function, and combined schemes with oral hypoglycemia. In this context vlidagliptin gathers valuable evidence on effectiveness and safety that allows supporting sustained clinical decisions. To highlight the benefits for elderly patients, a particularly fragile group and vulnerable to cardiovascular events
Authors and Affiliations
Forero, V. , Ribón Quintero, G. , & Echeverry-Raad, J.
Keywords
Related Articles
- EP ID EP694621
- DOI https://doi.org/10.26752/cuarzo.v24.n1.345
- Views 161
- Downloads 0
Critical outcomes in pediatric patients with pulmonary hypertension and congenital cardiopathy carried out to diagnostic heart catheterization in the Cardiovascular Hospital of Soacha between 2013 and 2016
BACKGROUND: For every thousand live births in Colombia, two to three present some type of cardiac congenital anomaly; the majority of them will be associated with the development of pulmonary hypertension, which is a pat...
Open Lip Schizencephaly: A Case Report
Schizencephaly is an extremely rare congenital structural disorder presented in 1.54/100,000 births. In this article, we present one of the few cases of schizencephaly reported in Colombia, in which the linguistic barrie...
Vildagliptin in diabetic type 2 patients with cardiovascular risk or renal impairment. Review of the literatura.
Introduction: Commonly prescribed agents for the treatment of type 2 diabetes (T2DM) have restrictions on use in patients with car-diovascular or renal function impairment. Published studies on dipeptidyl peptidase-4 inh...
Scientific production and burnout syndrome in teachers of public universities of Cesar in Colombia
BACKGROUND: The aim of this research is to analyse the scientific production and burnout syndrome in teachers of Public Universities of the Department of Cesar - Colombia. METHODS: The study was based on an...
Syndrome febril unknown, high probability of brucellosis, case report
Brucellosis, caused by the gram negative bacterium Brucella spp, is one of the great imitators in the world of infectious diseases, can simulate various multisystem diseases, exhibit a broad clinical poly-morphism that f...